| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_5941305510c5714dfa0a0d94047e1e04 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-505
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-94
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-92
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-64
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-73
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-732
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-71
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-622
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-31 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-2896
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-2809
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-395
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-28 |
| filingDate |
2020-06-30-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_8f97f6e245087e9df9a167854e028aec
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_87b0f45a10068e709369d708864e939d
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_1c328ed2910314c23e08ba577c3eccb1
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_be3bda28524adc4067107e420885bf7f
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_65ffd08f8a7b1fc853d81b77023d6d15
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_fc051ef0590ad9c85cfc4041231536fe
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_8c6ea06e43974e3ef8080330eb906d48 |
| publicationDate |
2021-01-07-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
WO-2021003189-A1 |
| titleOfInvention |
Heterodimeric antibodies that bind to cd38 and cd3 |
| abstract |
The present disclosure provides heterodimeric antibodies that bind to two different target antigens at the same time. In one embodiment, the heterodimeric antibodies are bispecific antibodies. In one embodiment, the heterodimeric antibodies comprise three polypeptides including: a first polypeptide comprising an scFv-Fc fusion polypeptide; a second polypeptide comprising an immunoglobulin heavy chain; and a third polypeptide comprising an immunoglobulin light chain. In one embodiment, the first polypeptide includes one or more point mutations that confer increased thermal-stability to the first polypeptide. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2023015170-A3
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2022217048-A1 |
| priorityDate |
2019-07-01-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |